We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
Read MoreHide Full Article
Key Takeaways
Pfizer posted Q1 earnings of $0.92 per share, crushing EPS expectations of $0.64 by 43%.
Trading near multi-year lows of $20 a share, investors may be eyeing Pfizer's stock for a continued rebound.
Pfizer is on track to exceed its net cost savings targets amid declining revenue from COVID-related products.
Pfizer (PFE - Free Report) shares spiked +3% in Tuesday’s trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations this morning.
Still, Pfizer stock has fallen 10% year to date and hasn’t provided the defensive hedge that many of its Zacks Large Cap Pharmaceutical peers have been able to provide, such as AbbVie (ABBV - Free Report) , Eli Lilly (LLY - Free Report) , and Johnson & Johnson (JNJ - Free Report) .
That said, investors may be eyeing Pfizer stock for a continued rebound with PFE still trading near multi-year lows of $20 a share.
Image Source: Zacks Investment Research
Pfizer’s Q1 Results
Navigating what it called a dynamic operating environment, Pfizer posted Q1 earnings of $0.92 per share, crushing EPS expectations of $0.64 by 43% and rising from $0.82 a share in the prior year quarter. Pfizer also highlighted that it’s on track to exceed its net cost savings targets. This comes as Pfizer has experienced declining revenue from COVID-related products along with discouraging clinical results for its weight loss drug, which would help the company compete with Eli Lilly and Novo Nordisk (NVO - Free Report) .
Posting mixed results, Pfizer’s Q1 sales of $13.71 billion missed estimates of $13.83 billion and were down from $14.87 billion a year ago. However, it's noteworthy that Pfizer has exceeded the Zacks EPS Consensus for 11 consecutive quarters with a very impressive average earnings surprise of 43.48% in its last four quarterly reports.
Image Source: Zacks Investment Research
Pfizer Reaffirms Its Full-Year Guidance
Reassuringly, Pfizer reaffirmed its full-year fiscal 2025 guidance, including revenues in the range of $61 billion-$64 billion, with Zacks projections currently at $63.48 billion. Pfizer still expects adjusted FY25 EPS at $2.80-$3.00, with the Zacks Consensus at $2.99.
Pfizer’s “Cheap” P/E Valuation
Most appealing to long-term investors is that Pfizer stock is trading near its decade-long low in terms of price to forward earnings at 7.7X and well below the high of 20.1X during this period. PFE also trades at a noticeable discount to the benchmark S&P 500’s 21.3X forward earnings multiple and its Zacks industry average of 16.4X.
Image Source: Zacks Investment Research
Pfizer’s Enticing Dividend
At current levels, Pfizer’s annual dividend also stands out with a 7.46% yield that towers over its industry’s 2.51% average and the benchmark’s 1.33%. Although Pfizer lost its status as a dividend aristocrat during the 2008 financial crisis, the company has now increased its dividend for 16 consecutive years.
Image Source: Zacks Investment Research
Conclusion & Final Thoughts
Following its Q1 report, Pfizer stock sports a Zacks Rank #2 (Buy). Corresponding with such, earnings estimate revisions for FY25 and FY26 are up over the last 30 days, and this trend could continue with Pfizer blowing away EPS expectations while highlighting its cost-saving initiatives.
This would certainly bolster Pfizer’s “cheap” P/E valuation and may lead to an extended rally as PFE does appear to offer long-term value to shareholders, considering its enticing dividend.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
Key Takeaways
Pfizer (PFE - Free Report) shares spiked +3% in Tuesday’s trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations this morning.
Still, Pfizer stock has fallen 10% year to date and hasn’t provided the defensive hedge that many of its Zacks Large Cap Pharmaceutical peers have been able to provide, such as AbbVie (ABBV - Free Report) , Eli Lilly (LLY - Free Report) , and Johnson & Johnson (JNJ - Free Report) .
That said, investors may be eyeing Pfizer stock for a continued rebound with PFE still trading near multi-year lows of $20 a share.
Image Source: Zacks Investment Research
Pfizer’s Q1 Results
Navigating what it called a dynamic operating environment, Pfizer posted Q1 earnings of $0.92 per share, crushing EPS expectations of $0.64 by 43% and rising from $0.82 a share in the prior year quarter. Pfizer also highlighted that it’s on track to exceed its net cost savings targets. This comes as Pfizer has experienced declining revenue from COVID-related products along with discouraging clinical results for its weight loss drug, which would help the company compete with Eli Lilly and Novo Nordisk (NVO - Free Report) .
Posting mixed results, Pfizer’s Q1 sales of $13.71 billion missed estimates of $13.83 billion and were down from $14.87 billion a year ago. However, it's noteworthy that Pfizer has exceeded the Zacks EPS Consensus for 11 consecutive quarters with a very impressive average earnings surprise of 43.48% in its last four quarterly reports.
Image Source: Zacks Investment Research
Pfizer Reaffirms Its Full-Year Guidance
Reassuringly, Pfizer reaffirmed its full-year fiscal 2025 guidance, including revenues in the range of $61 billion-$64 billion, with Zacks projections currently at $63.48 billion. Pfizer still expects adjusted FY25 EPS at $2.80-$3.00, with the Zacks Consensus at $2.99.
Pfizer’s “Cheap” P/E Valuation
Most appealing to long-term investors is that Pfizer stock is trading near its decade-long low in terms of price to forward earnings at 7.7X and well below the high of 20.1X during this period. PFE also trades at a noticeable discount to the benchmark S&P 500’s 21.3X forward earnings multiple and its Zacks industry average of 16.4X.
Image Source: Zacks Investment Research
Pfizer’s Enticing Dividend
At current levels, Pfizer’s annual dividend also stands out with a 7.46% yield that towers over its industry’s 2.51% average and the benchmark’s 1.33%. Although Pfizer lost its status as a dividend aristocrat during the 2008 financial crisis, the company has now increased its dividend for 16 consecutive years.
Image Source: Zacks Investment Research
Conclusion & Final Thoughts
Following its Q1 report, Pfizer stock sports a Zacks Rank #2 (Buy). Corresponding with such, earnings estimate revisions for FY25 and FY26 are up over the last 30 days, and this trend could continue with Pfizer blowing away EPS expectations while highlighting its cost-saving initiatives.
This would certainly bolster Pfizer’s “cheap” P/E valuation and may lead to an extended rally as PFE does appear to offer long-term value to shareholders, considering its enticing dividend.